France has become one of Europe’s most attractive countries for decentralized clinical trials (DCTs). With its highly qualified healthcare professionals, dense network of independent nurses and strong clinical research ecosystem, the country offers excellent conditions for bringing clinical trial procedures directly to patients.
For international pharmaceutical companies, biotechnology firms and CROs, however, one operational challenge remains: identifying a reliable home nursing provider capable of delivering protocol-compliant services across the entire country.
Choosing the right operational partner has a direct impact on recruitment, patient retention, protocol compliance and overall study quality.
This article explains how home nursing works in France, which studies can benefit from decentralized approaches, the regulatory considerations sponsors should understand, and the criteria for selecting a trusted home nursing vendor.
Why France Is an Attractive Market for Decentralized Clinical Trials
France has long been recognized as one of Europe’s leading countries for clinical research. Every year, hundreds of international studies are conducted across university hospitals, cancer centers and specialist research institutions.
Several factors make France particularly well suited to decentralized clinical trials:
- A universal healthcare system ensuring high-quality standards
- Experienced principal investigators across all therapeutic areas
- Strong regulatory oversight
- High standards of patient safety and data quality
- Excellent geographical coverage, including rural areas
- A nationwide network of more than 90 000 independent community nurses
These strengths allow sponsors to combine traditional investigator sites with home-based clinical procedures, reducing patient burden without compromising protocol quality.
What Is a Decentralized Clinical Trial?
A decentralized clinical trial (DCT) is a clinical study in which some study activities traditionally performed at an investigational site are carried out closer to the participant, often in the patient’s home.
Most studies today are hybrid rather than fully decentralized.
Typical home-based procedures include:
- Blood collection
- Pharmacokinetic (PK) sampling
- Urine collection
- ECG recording
- Vital signs assessment
- Administration of investigational medicinal products (where permitted)
- Patient questionnaires
- Safety follow-up visits
- Drug accountability
- Sample processing and shipment
By reducing unnecessary travel, DCTs improve the participant experience while maintaining high-quality clinical data.
Why home nursing has become essential for modern clinical trials
Home nursing is no longer simply a patient convenience.
It has become an operational strategy that helps sponsors solve some of the biggest challenges in clinical development:
- Slow patient recruitment
- High dropout rates
- Geographic limitations
- Missed protocol windows
- Participant fatigue
- Limited site capacity
Instead of asking patients to travel several hours for routine assessments, qualified nurses can perform many protocol-defined procedures directly at home while maintaining Good Clinical Practice (GCP) standards.
This approach is particularly valuable for long studies requiring frequent visits.
Which Clinical Trials Are Best Suited for Home Nursing?
Although decentralized approaches can be implemented across many study designs, some therapeutic areas benefit particularly from home nursing.
These include:
Oncology
Cancer patients often experience fatigue, immunosuppression and complex treatment schedules. Home visits reduce unnecessary hospital travel while maintaining close clinical monitoring.
Rare Diseases
Rare disease patients are geographically dispersed. Home nursing enables broader recruitment without requiring patients to relocate near expert centers.
Neurology
Patients with Alzheimer’s disease, Parkinson’s disease or multiple sclerosis frequently experience mobility or cognitive limitations that make travel difficult.
Autoimmune Diseases
Studies involving biologics administered by subcutaneous injection are particularly suitable for home visits.
Cardiovascular Diseases
Protocols requiring repeated ECGs, blood pressure monitoring or biomarker collection can often be safely performed in the patient’s home.
Pediatrics
Reducing travel significantly decreases the burden on families and improves study retention.
Geriatrics
Older adults often depend on caregivers or medical transport. Home visits make participation considerably easier.
What Can Home Nurses Perform During a Clinical Trial?
Depending on the study protocol and French regulations, home nurses may perform:
- Blood sampling
- PK collections
- Urine sampling
- Vital signs
- Weight measurements
- Temperature monitoring
- ECG acquisition
- Administration of investigational medicinal products
- Observation following IMP administration
- Adverse event reporting
- Drug accountability
- Sample centrifugation
- Cold-chain preparation
- Shipment coordination
Every activity must follow the protocol, sponsor SOPs and applicable GCP requirements.
As a matter of fact, phase I to IV trials, as well as post-marketing surveillance studies can be opportunities for home nursing integration.
Regulatory considerations for home nursing in France
International sponsors frequently ask whether home nursing is permitted in France.
The answer is yes—provided that the study is appropriately designed and complies with applicable French regulations.
Several aspects should be assessed during protocol development:
- Which procedures may legally be performed at home
- Scope of nursing practice under French law
- Investigator onboarding
- GCP compliance
- Informed consent procedures
- Biological sample handling
- Cold-chain management
- Data protection requirements
- Emergency procedures
Because regulations vary between countries, sponsors generally benefit from working with a local partner who understands both the French healthcare system and clinical research requirements.
How to choose a home nursing vendor in france
Selecting a home nursing provider should involve more than simply identifying nurses.
Sponsors should evaluate whether the vendor can manage the entire operational workflow.
Key criteria include:
Nationwide Coverage
Can nurses be deployed anywhere in France? Can multisites be handled?
Clinical Research Experience
Does the provider understand GCP, protocol deviations and sponsor expectations?
Protocol-Specific Training
How are nurses trained before each study?
Logistics Expertise
Can the provider manage PK sampling, centrifugation, cold-chain logistics and courier coordination?
Quality Management System
Is there documented quality oversight?
Project Management
Is there a dedicated operational team coordinating nurses, sites and CROs?
Digital Infrastructure
Can scheduling, visit documentation and communication be managed efficiently?
Why international sponsors choose libheros
libheros is France’s leading operational platform for home nursing in decentralized clinical trials.
Rather than simply providing nurses, libheros coordinates the entire home visit programme, acting as the operational interface between sponsors, CROs, investigational sites and healthcare professionals.
Its model enables international sponsors to activate decentralized clinical trial services quickly while ensuring consistent execution across France.
Nationwide Network
More than 22,000 independent nurses provide nationwide coverage, including remote and underserved regions.
Clinical Trial Expertise
Each participating nurse receives protocol-specific and GCP training before performing study procedures. GCP training is Transcelerate pharma-proofed.
Operational Excellence
libheros manages:
- Nurse identification
- Visit scheduling
- Training
- Logistics
- Biological sample coordination
- Cold-chain management
- Operational reporting
- Site coordination
Regulatory Expertise
libheros actively contributes to the development of decentralized clinical trials in France through participation in national industry working groups, including AFCROs and France Biotech.
This involvement enables sponsors to work with a partner closely aligned with the evolving French regulatory environment.
Impactful use cases
From Phase II to Phase IV studies, libheros has delivered home nursing services for pharmaceutical, biotechnology, medical device and academic sponsors across a broad range of therapeutic areas, including oncology, pulmonology, gastroenterology, gynecology and ophthalmology.
libheros experience covers complex protocol procedures such as PK blood sampling with bedside centrifugation, investigational product administration, vital signs assessments, medical device evaluation, biological sample collection, treatment adherence monitoring and remote patient follow-up. This broad operational experience enables international sponsors to implement decentralized clinical trial activities confidently, regardless of study design or therapeutic area.
Why the Right Home Nursing Partner Matters
For sponsors running multinational studies, France offers significant opportunities for decentralized research.
However, successful implementation depends on more than recruiting nurses.
A home nursing partner must combine clinical expertise, operational coordination, regulatory knowledge and nationwide logistics into a single, reliable service.
Choosing an experienced French provider helps reduce operational complexity, improve protocol compliance and deliver a better participant experience throughout the study.
Planning a Decentralized Clinical Trial in France?
Whether you are designing a hybrid study or expanding an international decentralized clinical trial into France, selecting the right operational partner is critical.
libheros supports pharmaceutical companies, biotechnology firms and CROs with nationwide home nursing services, protocol-specific training, logistics coordination and operational project management, enabling sponsors to deliver patient-centric clinical trials while maintaining the highest standards of quality and compliance.
Click here to ontact our clinical operations team to discuss your next study in France, who all speak English !
Yes, depending on the protocol, the product and applicable French regulations.
Yes, when specified in the protocol and supported by appropriate logistics.
Yes. Many hybrid decentralized clinical trials are currently conducted in France.
Nurses receive protocol-specific training, GCP instruction and operational guidance before performing study procedures.
Sponsors should assess nationwide coverage, clinical research experience, logistics capabilities, quality systems including instant visit report forms, regulatory expertise and project management resources.
